Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Trametinib decreases cell viability in RAS-mutated RMS in vitro.
  • Fig. S2. Trametinib induces G1 arrest and differentiation in RAS-mutated RMS.
  • Fig. S3. ERK2 is associated with developmental gene regulation in RAS-mutated cancer cell lines.
  • Fig. S4. MYOG associates with opened chromatin in trametinib-treated RMS cells.
  • Fig. S5. Super-enhancers in RAS-mutated RMS cell lines correlate with super-enhancers in RAS-mutated RMS tumors.
  • Fig. S6. RAS-dependent super-enhancers are not observed in human skeletal muscle myoblasts.
  • Fig. S7. MEK inhibition delays tumor growth in RD xenografts.
  • Fig. S8. Combination of trametinib and BMS-754807 delays tumor growth in RD xenografts.
  • Fig. S9. MEK inhibition induces transcriptional reprogramming analogous to myogenic differentiation in FN-RMS.
  • References (7789)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Dose response as %AUC for RMS and normal cell lines.
  • Table S2 (Microsoft Excel format). Differentially expressed genes in SMS-CTR treated with trametinib or SCH772984.
  • Table S3 (Microsoft Excel format). Differentially expressed genes in RD treated with trametinib or MEK1 siRNA SMS-CTR.
  • Table S4 (Microsoft Excel format). GSEA SMS-CTR treated with trametinib.
  • Table S5 (Microsoft Excel format). GSEA RD treated with trametinib.
  • Table S6 (Microsoft Excel format). HSMMdiff_UP gene set.
  • Table S7 (Microsoft Excel format). ERK2 ChIP-seq peaks.
  • Table S8 (Microsoft Excel format). Trametinib-changed DNase-seq peaks.
  • Table S9 (Microsoft Excel format). MYOD, MYC, and MYOG peaks in SMS-CTR treated with trametinib.
  • Table S10 (Microsoft Excel format). Super-enhancers with and without trametinib.
  • Table S11 (Microsoft Excel format). Gene Expression Omnibus data sets used in this analysis.
  • Table S12 (Microsoft Excel format). STR genotyping of RMS cell lines used in this study.
  • Table S13 (Microsoft Excel format). Primers used in this study.
  • Table S14 (Microsoft Excel format). Vectors used in this study.
  • Table S15 (Microsoft Excel format). Antibodies used in this study.
  • Table S16 (Microsoft Excel format). RAS-dependent_SE_DOWN and Myogenic_SE_UP gene sets.
  • Table S17 (Microsoft Excel format). Pilot 6 × 6 matrix screen excess HSA.
  • Table S18 (Microsoft Excel format). Matrix screen (10 × 10) excess HSA.

[Download Tables S1 to S18]